The fact
This breakthrough represents significant progress in neurodegenerative disease treatment.
Clinical trials may accelerate drug development and patient access.
Click the link to read an article on the topic:
Observed impact
Potentiel ralentissement de la neurodégénérescence chez patients Alzheimer
Accélération des essais cliniques Phase III prévue en 2026